Glenmark Pharmaceuticals Ltd - Company Profile
Powered by 
All the sales intelligence you need on Glenmark Pharmaceuticals Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Glenmark Pharmaceuticals Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Glenmark Pharmaceuticals Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Glenmark Pharmaceuticals Ltd (Glenmark) is a global pharmaceutical company engaged in research-led activities across branded, generics, and over-the-counter segments. The company focuses on developing products in the therapy areas of Respiratory, Dermatology, and Oncology. The company markets its products under the brands Beat, Tiogiva, Fabiflu, Telma, Ryaltris, Candid, Ascoril, Razel EZ, Bon D Light Drops, Lulican, and Momate. Glenmark's products serve patients across various industries, including healthcare and pharmaceuticals, with applications in treating complex medical conditions. Glenmark has manufacturing facilities in India, Argentina, the US, and the Czech Republic. The company markets its products in the Americas, Europe, the Middle East, North Africa (MENA), and Asia. Glenmark is headquartered in Mumbai, Maharashtra, India.
Headquarters
India
Address
B. D. Sawant Marg, Chakala, Off Western Express Highway, Glenmark House, Andheri (E), Mumbai, Maharashtra, 400099
Website
www.glenmarkpharma.com
Telephone
91 22 40189999
No of Employees
13,477
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GLENMARK (NSE)
Revenue (2025)
$1.9B
27.5%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
30.1%
(2025 vs 2024)
Market Cap*
$6.5B
Net Profit Margin (2025)
XYZ
2.0%
(2025 vs 2024)
* As of and is in US$
Glenmark Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Branded Formulations: | Contract Development and Manufacturing | Beat |
| Oncology | Tiogiva | |
| Respiratory | Fabiflu | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In March, the company introduced Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg. |
| 2026 | New Products/Services | In March, the company launched Men's GLN-Minoxidil 5% w/w (50 mg/g) Topical Aerosol Foam in Canada. |
| 2026 | Contracts/Agreements | In January, the company signed a commercial agreement with AcuCort AB for the marketing and distribution of AcuCort’s product, Zeqmelit in Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine. |
Competitor Comparison
| Key Parameters | Glenmark Pharmaceuticals Ltd | Teva Pharmaceutical Industries Ltd | Viatris Inc | Sun Pharmaceutical Industries Ltd | Dr. Reddy's Laboratories Ltd |
|---|---|---|---|---|---|
| Headquarters | India | Israel | United States of America | India | India |
| City | Mumbai | Tel Aviv | Canonsburg | Mumbai | Hyderabad |
| State/Province | Maharashtra | Tel Aviv | Pennsylvania | Maharashtra | Telangana |
| No. of Employees | 13,477 | 31,173 | 30,000 | 43,000 | 26,944 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Glenn Saldanha | Chief Executive Officer; Managing Director | Executive Board | 2011 | - |
| Shweta Munjal | Corporate Social Responsibility Officer; Chief Communications Officer | Senior Management | 2024 | - |
| Alind Sharma | President; Chief Human Resources Officer | Senior Management | 2022 | - |
| Indrajit Bose | Chief Quality Officer; President | Senior Management | 2023 | - |
| Anurag Mantri | Director; Global Chief Financial Officer | Executive Board | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer